By globally harmonizing regulations for the approval of oncology therapies subject to clinical trials, it would be possible to reduce the number of global cancer-related deaths per year by 10% to 20%, or 1 million to 2 million lives. That’s because the lack of such an international system is slowing the approval of treatments around the world, according to research that we conducted.
We Need a Global System for Testing and Approving Cancer Treatments
A standardized international process could reduce cancer deaths by 10–20%, saving millions of lives.
October 18, 2022
HBR Staff/JGI/Tom Grill/Lesia_G/Getty Images
Summary.
The lack of an international system for the approval of new cancer therapies subject to clinical trials is costing as many as 2 million lives per year, according to research conducted by the authors estimate. In this article, they recommend five steps for harmonizing countries’ regulations. Doing so, they say, would allow for clinical trials in all participating nations to follow the same criteria. Drugs would get approved faster and become available to more patient populations sooner, which would prolong the lives of those who are in critical need of treatment.